Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00103298CT.gov Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00089401CT.gov Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver | — | Completed | — | — | — |
NCT00030082CT.gov Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer | — | Completed | — | — | — |
NCT00020501CT.gov Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Completed | — | — | — |
NCT00019786CT.gov Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Melphalan (this asset) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P3 | B · 63 |
| Fluorouracilum | I-Mab Biopharma US Limited | P3 | BB |
| Irinotecan | Incyte Corporation | P3 | BB |
| Nivestim | Mayo Clinic | P3 | BB |
| Cyclophosphamide | InSilico Medicine Hong Kong Limited | P2/3 | BB |
| Pembrolizumab | InSilico Medicine Hong Kong Limited | P2/3 | BB |
| Letrozole | UNICANCER | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | National Cancer Institute (NCI) | P2/3 | BB |
| Anastrozole | UNICANCER | P3 | BB |
+42 more in the Metastatic Malignant Neoplasm cohort
Other indications for Melphalan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 76 |
| Cancer Of Unknown Primary Site | — | P2/3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Melphalan in Metastatic Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/melphalan-metastatic-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →